Morgan Stanley削减了Eli Lilly的价格目标,尽管公司损失了收入估算,但仍保持着正面的评级。 Morgan Stanley cut Eli Lilly's price target but kept a positive rating, despite the company missing earnings estimates.

摩根斯坦利将Eli Lilly和公司(LLY)的价格目标降至1 124美元,同时保持超重评级。 Morgan Stanley lowered Eli Lilly and Company's (LLY) price target to $1,124 while maintaining an overweight rating. 尽管如此,公司的共识评级仍然是“Moderate Buy”,目标价格为1 017.67美元。 Despite this, the company's consensus rating remains "Moderate Buy" with a target price of $1,017.67. 机构所有权占82.53%,一些公司调整了其持有量。 Institutional ownership stands at 82.53%, with several firms adjusting their holdings. Elilly报告Q4收入为每股5.32美元,损失估计数为0.13美元。 Eli Lilly reported Q4 earnings of $5.32 per share, missing estimates by $0.13. 该公司的股票市场上限为712.65亿美元,P/E比率为64.19。 The company's stock has a market cap of $712.65 billion and a P/E ratio of 64.19.